Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

MR-Lymphography and Lymph Node Staging in Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Radboud University.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Radboud University
ClinicalTrials.gov Identifier:
NCT00185029
First received: September 13, 2005
Last updated: September 14, 2005
Last verified: September 2005
  Purpose

This proposal is targeted at all patients with prostate cancer who are candidates for either curative surgery or curative radiotherapy in whom lymph node staging is indicated. Recently, it has been shown, that in patients with PSA <10 ng/ml and Gleason score < 7 the risk of lymph node metastases is low. Therefore, unnecessary PLND and non-invasive imaging can be avoided safely in this group. PLND is nowadays performed only in patients with intermediate or high risk for nodal metastases. Thus the subgroup of patients targeted in this study consists of patients with prostate cancer with a PSA >10 ng/ml and Gleason score > 6.

  • If the high sensitivity (90%) and negative predictive value (96%) of MRL can be validated in the 8 participating centres, in patients with a negative MRL invasive PLND may be avoided.
  • In patients with a positive MRL with enlarged nodes (larger than 8 mm) histological diagnosis may be obtained by imaged guided biopsy, and thus also in these patients avoid PLND. A limitation of image guide biopsy, however, is the 30% false negative rate. [Barentsz, Oyen, Wolf]
  • In patients with positive small nodes (smaller than 8 mm) the urologist may, focussed by the MRL findings of a positive node outside his “surgical field-of-view”, extend his dissection, and thus improve his accuracy.
  • Based on the expected higher sensitivity of MRL this technique will completely replace CT-scanning.

Condition Intervention Phase
Prostatic Neoplasms
Lymphatic Metastasis
Procedure: Ferumoxtran-10 enhanced MRI (MRL)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer?

Resource links provided by NLM:


Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Primary outcome parameters concern accuracy sensitivity, specificity, PPV and NPV of both MRL and CT

Secondary Outcome Measures:
  • Secondary outcome measures are costs per patient for each strategy. Besides this, quality of life after 6 months of follow up will be part of the analysis.

Estimated Enrollment: 396
Study Start Date: April 2002
Estimated Study Completion Date: August 2005
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • prostate cancer
  • PSA > 10 or Gleason > 6 or T3 tumor
  • adult male
  • scheduled for lymphadenectomy
  • written informed consent

Exclusion Criteria:

  • Patient having undergone chemotherapy or radiotherapy of the pelvic area
  • patient having undergone resection of the pelvic tumor with lymphadenectomy
  • Patient included in another trial involving an investigational drug
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00185029

Locations
Netherlands
NKI AVL
Amsterdam, Netherlands, 1066 CX
Catharina Hospital
Eindhoven, Netherlands, 5602 ZA
Ziekenhuis Zeeuws-Vlaanderen
Terneuzen, Netherlands, 4535 PA
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Principal Investigator: Jelle Barentsz, Phd MD Radboud University
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00185029     History of Changes
Other Study ID Numbers: sinerem1, 945-02-051
Study First Received: September 13, 2005
Last Updated: September 14, 2005
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:
prostate
ferumoxtran-10
lymph nodes
USPIO

Additional relevant MeSH terms:
Lymphatic Metastasis
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasm Metastasis
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Prostatic Diseases
Urogenital Neoplasms
Ferumoxtran-10
Contrast Media
Diagnostic Uses of Chemicals
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 25, 2014